Treatment of acute toxoplasmosis with intravenous clindamycin

The interim results are presented of an ongoing large-scale, prospective, randomized study to determine the potential role of clindamycin in the treatment of toxoplasmic encephalitis. Data was available on 33 patients, 15 of whom received pyrimethamine p.o./clindamycin i.v. and then p.o., and 18 of...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical microbiology & infectious diseases 1991-03, Vol.10 (3), p.193-195
Main Authors: DANNEMANN, B. R, MCCUTCHAN, J. A, HESELTINE, P. N. C, LEEDOM, J. M, CLUMECK, N, MORLAT, P, REMINGTON, J. S, ISRAELSKI, D. M, ANTONISKIS, D, LEPORT, C, LUFT, B. J, CHIU, J, VILDE, J. L, NUSSBAUM, J. N, ORELLANA, M
Format: Article
Language:English
Subjects:
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiparasitic agents
Biological and medical sciences
Medical sciences
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c290t-5929f2dafec7b5e856fa51f6acd8d259dc1b03ed942f9973715753ea0aab472f3
cites cdi_FETCH-LOGICAL-c290t-5929f2dafec7b5e856fa51f6acd8d259dc1b03ed942f9973715753ea0aab472f3
container_end_page 195
container_issue 3
container_start_page 193
container_title European journal of clinical microbiology & infectious diseases
container_volume 10
creator DANNEMANN, B. R
MCCUTCHAN, J. A
HESELTINE, P. N. C
LEEDOM, J. M
CLUMECK, N
MORLAT, P
REMINGTON, J. S
ISRAELSKI, D. M
ANTONISKIS, D
LEPORT, C
LUFT, B. J
CHIU, J
VILDE, J. L
NUSSBAUM, J. N
ORELLANA, M
description The interim results are presented of an ongoing large-scale, prospective, randomized study to determine the potential role of clindamycin in the treatment of toxoplasmic encephalitis. Data was available on 33 patients, 15 of whom received pyrimethamine p.o./clindamycin i.v. and then p.o., and 18 of whom received pyrimethamine p.o./sulfadiazine p.o. The interim evaluation did not reveal a remarkable difference between the two regimens in the clinical or radiologic response.
doi_str_mv 10.1007/BF01964461
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15945357</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15945357</sourcerecordid><originalsourceid>FETCH-LOGICAL-c290t-5929f2dafec7b5e856fa51f6acd8d259dc1b03ed942f9973715753ea0aab472f3</originalsourceid><addsrcrecordid>eNpFkL1OwzAYRS0EEqGw8ARZYEAK-DeOBwaoKCBVYilz9NWxhVFiB9sF-vYEtVKnu5x7dHURuiT4lmAs7x4XmKia85ocoYJwJirOJDtGBVaMV0pSdorOUvrEE9xIWaD7VTSQB-NzGWwJepNNmcNvGHtIQ0gulT8uf5TO5wjfxodNKnXvfAfDVjt_jk4s9Mlc7HOG3hdPq_lLtXx7fp0_LCtNFc6VUFRZ2oE1Wq6FaURtQRBbg-6ajgrVabLGzHSKU6uUZJIIKZgBDLDmklo2Q9c77xjD18ak3A4uadP34M00qSVCccGEnMCbHahjSCka247RDRC3LcHt_0Pt4aEJvtpbIWnobQSvXTo0piVU0Yb9ASKWZiw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15945357</pqid></control><display><type>article</type><title>Treatment of acute toxoplasmosis with intravenous clindamycin</title><source>Springer Online Journal Archives</source><creator>DANNEMANN, B. R ; MCCUTCHAN, J. A ; HESELTINE, P. N. C ; LEEDOM, J. M ; CLUMECK, N ; MORLAT, P ; REMINGTON, J. S ; ISRAELSKI, D. M ; ANTONISKIS, D ; LEPORT, C ; LUFT, B. J ; CHIU, J ; VILDE, J. L ; NUSSBAUM, J. N ; ORELLANA, M</creator><creatorcontrib>DANNEMANN, B. R ; MCCUTCHAN, J. A ; HESELTINE, P. N. C ; LEEDOM, J. M ; CLUMECK, N ; MORLAT, P ; REMINGTON, J. S ; ISRAELSKI, D. M ; ANTONISKIS, D ; LEPORT, C ; LUFT, B. J ; CHIU, J ; VILDE, J. L ; NUSSBAUM, J. N ; ORELLANA, M ; the California Collaborative Treatment Group</creatorcontrib><description>The interim results are presented of an ongoing large-scale, prospective, randomized study to determine the potential role of clindamycin in the treatment of toxoplasmic encephalitis. Data was available on 33 patients, 15 of whom received pyrimethamine p.o./clindamycin i.v. and then p.o., and 18 of whom received pyrimethamine p.o./sulfadiazine p.o. The interim evaluation did not reveal a remarkable difference between the two regimens in the clinical or radiologic response.</description><identifier>ISSN: 0934-9723</identifier><identifier>EISSN: 1435-4373</identifier><identifier>DOI: 10.1007/BF01964461</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiparasitic agents ; Biological and medical sciences ; Medical sciences ; Pharmacology. Drug treatments</subject><ispartof>European journal of clinical microbiology &amp; infectious diseases, 1991-03, Vol.10 (3), p.193-195</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c290t-5929f2dafec7b5e856fa51f6acd8d259dc1b03ed942f9973715753ea0aab472f3</citedby><cites>FETCH-LOGICAL-c290t-5929f2dafec7b5e856fa51f6acd8d259dc1b03ed942f9973715753ea0aab472f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19732928$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>DANNEMANN, B. R</creatorcontrib><creatorcontrib>MCCUTCHAN, J. A</creatorcontrib><creatorcontrib>HESELTINE, P. N. C</creatorcontrib><creatorcontrib>LEEDOM, J. M</creatorcontrib><creatorcontrib>CLUMECK, N</creatorcontrib><creatorcontrib>MORLAT, P</creatorcontrib><creatorcontrib>REMINGTON, J. S</creatorcontrib><creatorcontrib>ISRAELSKI, D. M</creatorcontrib><creatorcontrib>ANTONISKIS, D</creatorcontrib><creatorcontrib>LEPORT, C</creatorcontrib><creatorcontrib>LUFT, B. J</creatorcontrib><creatorcontrib>CHIU, J</creatorcontrib><creatorcontrib>VILDE, J. L</creatorcontrib><creatorcontrib>NUSSBAUM, J. N</creatorcontrib><creatorcontrib>ORELLANA, M</creatorcontrib><creatorcontrib>the California Collaborative Treatment Group</creatorcontrib><title>Treatment of acute toxoplasmosis with intravenous clindamycin</title><title>European journal of clinical microbiology &amp; infectious diseases</title><description>The interim results are presented of an ongoing large-scale, prospective, randomized study to determine the potential role of clindamycin in the treatment of toxoplasmic encephalitis. Data was available on 33 patients, 15 of whom received pyrimethamine p.o./clindamycin i.v. and then p.o., and 18 of whom received pyrimethamine p.o./sulfadiazine p.o. The interim evaluation did not reveal a remarkable difference between the two regimens in the clinical or radiologic response.</description><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><issn>0934-9723</issn><issn>1435-4373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><recordid>eNpFkL1OwzAYRS0EEqGw8ARZYEAK-DeOBwaoKCBVYilz9NWxhVFiB9sF-vYEtVKnu5x7dHURuiT4lmAs7x4XmKia85ocoYJwJirOJDtGBVaMV0pSdorOUvrEE9xIWaD7VTSQB-NzGWwJepNNmcNvGHtIQ0gulT8uf5TO5wjfxodNKnXvfAfDVjt_jk4s9Mlc7HOG3hdPq_lLtXx7fp0_LCtNFc6VUFRZ2oE1Wq6FaURtQRBbg-6ajgrVabLGzHSKU6uUZJIIKZgBDLDmklo2Q9c77xjD18ak3A4uadP34M00qSVCccGEnMCbHahjSCka247RDRC3LcHt_0Pt4aEJvtpbIWnobQSvXTo0piVU0Yb9ASKWZiw</recordid><startdate>19910301</startdate><enddate>19910301</enddate><creator>DANNEMANN, B. R</creator><creator>MCCUTCHAN, J. A</creator><creator>HESELTINE, P. N. C</creator><creator>LEEDOM, J. M</creator><creator>CLUMECK, N</creator><creator>MORLAT, P</creator><creator>REMINGTON, J. S</creator><creator>ISRAELSKI, D. M</creator><creator>ANTONISKIS, D</creator><creator>LEPORT, C</creator><creator>LUFT, B. J</creator><creator>CHIU, J</creator><creator>VILDE, J. L</creator><creator>NUSSBAUM, J. N</creator><creator>ORELLANA, M</creator><general>Springer</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope></search><sort><creationdate>19910301</creationdate><title>Treatment of acute toxoplasmosis with intravenous clindamycin</title><author>DANNEMANN, B. R ; MCCUTCHAN, J. A ; HESELTINE, P. N. C ; LEEDOM, J. M ; CLUMECK, N ; MORLAT, P ; REMINGTON, J. S ; ISRAELSKI, D. M ; ANTONISKIS, D ; LEPORT, C ; LUFT, B. J ; CHIU, J ; VILDE, J. L ; NUSSBAUM, J. N ; ORELLANA, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c290t-5929f2dafec7b5e856fa51f6acd8d259dc1b03ed942f9973715753ea0aab472f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DANNEMANN, B. R</creatorcontrib><creatorcontrib>MCCUTCHAN, J. A</creatorcontrib><creatorcontrib>HESELTINE, P. N. C</creatorcontrib><creatorcontrib>LEEDOM, J. M</creatorcontrib><creatorcontrib>CLUMECK, N</creatorcontrib><creatorcontrib>MORLAT, P</creatorcontrib><creatorcontrib>REMINGTON, J. S</creatorcontrib><creatorcontrib>ISRAELSKI, D. M</creatorcontrib><creatorcontrib>ANTONISKIS, D</creatorcontrib><creatorcontrib>LEPORT, C</creatorcontrib><creatorcontrib>LUFT, B. J</creatorcontrib><creatorcontrib>CHIU, J</creatorcontrib><creatorcontrib>VILDE, J. L</creatorcontrib><creatorcontrib>NUSSBAUM, J. N</creatorcontrib><creatorcontrib>ORELLANA, M</creatorcontrib><creatorcontrib>the California Collaborative Treatment Group</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>European journal of clinical microbiology &amp; infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DANNEMANN, B. R</au><au>MCCUTCHAN, J. A</au><au>HESELTINE, P. N. C</au><au>LEEDOM, J. M</au><au>CLUMECK, N</au><au>MORLAT, P</au><au>REMINGTON, J. S</au><au>ISRAELSKI, D. M</au><au>ANTONISKIS, D</au><au>LEPORT, C</au><au>LUFT, B. J</au><au>CHIU, J</au><au>VILDE, J. L</au><au>NUSSBAUM, J. N</au><au>ORELLANA, M</au><aucorp>the California Collaborative Treatment Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of acute toxoplasmosis with intravenous clindamycin</atitle><jtitle>European journal of clinical microbiology &amp; infectious diseases</jtitle><date>1991-03-01</date><risdate>1991</risdate><volume>10</volume><issue>3</issue><spage>193</spage><epage>195</epage><pages>193-195</pages><issn>0934-9723</issn><eissn>1435-4373</eissn><abstract>The interim results are presented of an ongoing large-scale, prospective, randomized study to determine the potential role of clindamycin in the treatment of toxoplasmic encephalitis. Data was available on 33 patients, 15 of whom received pyrimethamine p.o./clindamycin i.v. and then p.o., and 18 of whom received pyrimethamine p.o./sulfadiazine p.o. The interim evaluation did not reveal a remarkable difference between the two regimens in the clinical or radiologic response.</abstract><cop>Berlin</cop><pub>Springer</pub><doi>10.1007/BF01964461</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0934-9723
ispartof European journal of clinical microbiology & infectious diseases, 1991-03, Vol.10 (3), p.193-195
issn 0934-9723
1435-4373
language eng
recordid cdi_proquest_miscellaneous_15945357
source Springer Online Journal Archives
subjects Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiparasitic agents
Biological and medical sciences
Medical sciences
Pharmacology. Drug treatments
title Treatment of acute toxoplasmosis with intravenous clindamycin
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T23%3A27%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20acute%20toxoplasmosis%20with%20intravenous%20clindamycin&rft.jtitle=European%20journal%20of%20clinical%20microbiology%20&%20infectious%20diseases&rft.au=DANNEMANN,%20B.%20R&rft.aucorp=the%20California%20Collaborative%20Treatment%20Group&rft.date=1991-03-01&rft.volume=10&rft.issue=3&rft.spage=193&rft.epage=195&rft.pages=193-195&rft.issn=0934-9723&rft.eissn=1435-4373&rft_id=info:doi/10.1007/BF01964461&rft_dat=%3Cproquest_cross%3E15945357%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c290t-5929f2dafec7b5e856fa51f6acd8d259dc1b03ed942f9973715753ea0aab472f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=15945357&rft_id=info:pmid/&rfr_iscdi=true